Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic
- 1 August 2024
- journal article
- research article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (7) , 2598-2606
Abstract
The sudden global crisis of COVID-19, driven by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), demands swift containment measures due to its rapid spread and numerous problematic mutations, which complicate the establishment of herd immunity. With escalating fatalities across various nations no foreseeable end in sight, there is a pressing need to create swiftly deployable, rapid, cost-effective detection, and treatment methods. While various steps are taken to mitigate the transmission and severity of the disease, vaccination is proven throughout mankind history as the best method to acquire immunity and circumvent the spread of infectious diseases. Nonetheless, relying solely on vaccination might not be adequate to match the relentless viral mutations observed in emerging variants of SARS-CoV-2, including alterations to their RBD domain, acquisition of escape mutations, and potential resistance to antibody binding. Beyond the immune system activation achieved through vaccination, it is crucial to develop new medications or treatment methods to either impede the infection or enhance existing treatment modalities. This review emphasizes innovative treatment strategies that aim to directly disrupt the virus’s ability to replicate and spread, which could play a role in ending the SARS-CoV-2 pandemic.Keywords
This publication has 69 references indexed in Scilit:
- N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infectionActa Biomaterialia, 2023
- Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamstersAntiviral Research, 2023
- Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infectionHematological Oncology, 2023
- Native and activated antithrombin inhibits TMPRSS2 activity and SARS‐CoV‐2 infectionJournal of Medical Virology, 2022
- Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A reviewJournal of Medical Virology, 2022
- In silico Studies on the Interaction between Mpro and PLpro From SARS‐CoV‐2 and Ebselen, its Metabolites and DerivativesMolecular Informatics, 2021
- Polysulfates Block SARS‐CoV‐2 Uptake through Electrostatic Interactions**Angewandte Chemie International Edition, 2021
- COVID-19 vaccines: rapid development, implications, challenges and future prospectsHuman Cell, 2021
- Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike‐ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics**Chemistry – A European Journal, 2020
- Otolaryngology during COVID-19: Preventive care and precautionary measuresAmerican Journal of Otolaryngology, 2020